Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
The incidence of invasive fungal infections (IFIs) continues to increase, largely due to the steady rise in the number of at-risk patients and the increased use of aggressive immunosuppressant agents. Many available treatments are often limited by concerns about efficacy, safety, drug interactions, and/or cost. Owing to the poor treatment outcomes of immunosuppressed patients with IFIs, new preventative and treatment strategies are being investigated. Among these are the aerosolized formulations of amphotericin B. Published experience with the use of aerosolized amphotericin B deoxycholate (AmBd) in the prevention of IFIs has raised concerns regarding challenges in drug administration and tolerability. However, evolving data regarding administration of lipid-based formulations of amphotericin B indicate potential advantages over AmBd in the prevention and adjunctive treatment of IFIs.
Drew
Richard
R
Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA. richard.drew@duke.edu
D000336:Aerosols; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D003840:Deoxycholic Acid / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D015994:Incidence; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D010713:Phosphatidylcholines / Q000008:administration & dosage* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
D000336:Aerosols; D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination